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Depression, smoking abstinence and HPA function
in women smokers
Ovide F. Pomerleau*, Cynthia S. Pomerleau, Sandy M. Snedecor, Stefanie Gaulrapp,
Rebecca Namenek Brouwery and Oliver G. Cameron
Department of Psychiatry, Nicotine Research Laboratory, University of Michigan, Ann Arbor, MI 48105, USA
To determine whether smokers with a history of depression are differentially susceptible to smoking withdrawal, depressed
mood induction and/or hypothalamic–pituitary–adrenal (HPA) axis dysregulation during smoking abstinence, 24 women
smokers with and without such a history were studied. During one 5-day interval, participants smoked ad libitum; during
a second they abstained. On day 4, the participants were exposed to the Velten mood induction procedure (VMIP). Parti-
cipants were then instructed to take 1 mg dexamethasone at 11 pm. At 4 pm on day 5, blood samples were withdrawn to
determine the cortisol and ACTH response. Despite lower baseline cotinine levels, history-positive participants displayed
more pronounced overall withdrawal distress than did history-negative participants, regardless of condition. The VMIP
increased depression as well as negative responses on other profile of mood states subscales. Despite many overall group
differences, no significant main effects for smoking condition nor interaction effects emerged. All participants evinced cor-
tisol suppression in response to dexamethasone during both conditions, but the degree of suppression did not differ as a
function of either abstinence or depression history. In history-positive smokers, however, ACTH levels trended toward over-
all elevation and showed almost no suppression during abstinence; thus exacerbation of HPA dysregulation in history-
positive smokers during smoking abstinence cannot be ruled out. Copyright # 2004 John Wiley & Sons, Ltd.
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INTRODUCTION
Considerable evidence has been presented that smok-
ing is overrepresented in individuals with diagnosable
or subclinical depression, or even with a history of
depression (Anda et al., 1990; Covey et al., 1990;
Glassman, 1993). And although the evidence is not
unequivocal (e.g. Ginsberg et al., 1995; Hall et al.,
1994; Hitsman et al., 2001), a number of studies have
shown that these smokers have greater difficulty in
quitting (e.g. Glassman et al., 1988; Glassman,
1993; Balabanis et al., 2001). To the extent that they
are successful, their quit attempts may be complicated
by the emergence of greater and more persistent with-
drawal symptomatology, particularly depressed mood
(e.g. Borrelli et al., 1996; Covey et al., 1990; Hall
et al., 1991; Kinnunen et al., 1996; Niaura et al.,
1999; Pomerleau et al., 2001; Glassman et al.,
2001)—although a higher likelihood of episodes of
depression in such smokers even when they are not
attempting to quit has also been noted (Tsoh et al.,
2000). An additional consideration is that depression
is more common in women than in men, with women
accounting for 61.2% of the total in lifetime prevalence
of depressive symptoms and 71.2% of major depressive
disorder (MDD)/dysthymia (Johnson et al., 1992;
Weissman et al., 1991). Moreover, although the asso-
ciation of smoking with depression has been shown to
be significant for both men and women, data from the
National Health and Nutrition Epidemiological
Survey (Anda et al., 1990), the St. Louis ECA study
(Glassman et al., 1990) and the San Francisco survey
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(Perez-Stable et al., 1990) suggest that this relation-
ship may be more pronounced in women than in men.
People with a history of MDD are more susceptible
to HPA-axis dysregulation (Carroll et al., 1981;
Young et al., 1991,) and clinical observations by
Glassman (1993) suggest that chronic nicotine expo-
sure may help to maintain affective equilibrium and
‘normalize’ HPA-axis function in certain people.
Thus, when smokers with a history of MDD stop
smoking, in addition to manifestations of clinical
depression or severe dysphoria, there may be a
rebound effect on the HPA-axis resulting in a loss of
feedback inhibition of cortisol. Resumption of smok-
ing has been found to terminate depression/dysphoria
(Fagerström et al., 1991)—within several hours in
some cases (Glassman, 1993). While much uncer-
tainty remains about biobehavioral mechanisms that
might link smoking and depression (see Carmody,
1989), nicotine is known to have important effects on
central acetylcholine and catecholamines (Pomerleau
and Pomerleau, 1984), both of which have been
shown to play a role in the etiology of depression
(Siever, 1987; Janowsky and Risch, 1987); moreover,
nicotine is known to affect brain regions that influence
mood and well-being (Carmody, 1989; Pomerleau and
Rosecrans, 1989). It is plausible, therefore, that the
same genetic variations in brain neurotransmitter sys-
tems that influence the probability of major depres-
sion also increase the probability of smoking by
enhancing the degree to which nicotine provides rein-
forcement via affective normalization (Kendler et al.,
1993). Further, in people whose psychological and/or
physiological adaptability is compromised, nicotine
may serve to maintain homeostasis in critical systems
such as the HPA-axis; for such people, nicotine use
may constitute a coping strategy for meeting the chal-
lenges of daily living (see Pomerleau and Pomerleau,
1984).
In order to determine whether the reinforcing value
of nicotine self-administration is enhanced in
depressed individuals by the drug’s affect-normaliz-
ing properties and its ability to protect against the
hypothalamic–pituitary–adrenal (HPA) axis dysregu-
lation that often characterizes episodes of depres-
sion—as indicated by elevated cortisol and ACTH
levels following dexamethasone administration—a
laboratory test was conducted of women smokers with
and without a history of depression. We also wished to
determine susceptibility to induction of depressed
mood in history-positive and history-negative women
smokers. Participants were studied during ad libitum
smoking and over the first few days of abstinence from
smoking, the interval during which, despite consider-
able individual variability (Piasecki et al., 2000),
craving and cognitive/affective withdrawal sympto-
matology typically peak (Ward et al., 2001).
Our expectations were as follows: (1) Over the
course of 3 days of smoking abstinence, history-posi-
tive (HXþMDD) smokers would experience withdra-
wal symptomatology of greater magnitude and
duration than history-negative (HXMDD) smokers;
(2) After 3 days of abstinence from smoking, history-
positive smokers would be more susceptible to
induction of dysphoria than would history-negative
smokers; (3) After 4–5 days of abstinence from
smoking, history-positive smokers would show HPA
dysregulation as indicated by post-DST cortisol
and ACTH levels, whereas history-negative




Twenty-four female smokers, 12 with and 12 without a
history of depression, were recruited from the general
community through local newspaper advertisements
and posters. Participants were required to meet the fol-
lowing criteria: between 20 and 55 years of age; pre-
menopausal; in good health; weight 100 pounds;
score 3 on the Fagerström test of nicotine depen-
dence (FTND; Fagerström et al., 1991; Heatherton
et al., 1991; Pomerleau et al., 1994); smoking at least
10 cigarettes per day; and smoking at the current rate
for at least 1 year. Candidates were excluded for the
following: current use of CNS or cardiovascular-act-
ing drugs; current use of antidepressant or antipsycho-
tic medication; cardiac, vascular, pulmonary or gastric
disease; hypertension; history of throat irritation or
severe sinus infection; allergy to nicotine; history of
seizures; history of abuse of drug or alcohol within
1 year prior to the study; history of anorexia
nervosa; 15% below normal weight; regular use of
other tobacco products such as cigars or pipes; and
current depression (episode within past 6 months).
Candidates were also excluded if they were currently
pregnant or breastfeeding, had been pregnant or
breastfeeding within the past 3 months, or were at risk
of becoming pregnant.
A total of 643 interested people were telephone-
screened, 147 of whom met preliminary qualifications
and were invited to come into the laboratory for a
screening interview. Of these, 35 opted not to partici-
pate further, 24 failed to show up for an appointment,
41 kept the appointment but were disqualified due to
468 o. f. pomerleau ET AL.
Copyright # 2004 John Wiley & Sons, Ltd. Hum Psychopharmacol Clin Exp 2004; 19: 467–476.
smoking criteria or medical reasons, and the remain-
ing 47 candidates qualified for participation in the
study. Of these, eight lost interest and/or did not show
up for scheduled laboratory sessions, seven could not
be re-contacted after the initial interview, two decided
that they did not have enough time to participate, two
smoked during the abstinence phase and had to be dis-
qualified, two were dropped due to problems main-
taining adequate blood flow during laboratory
sessions, and two could not be enrolled because they
failed to qualify for unfilled cells; ultimately, 24 par-
ticipants completed the protocol.
Procedure
The protocol for this study was approved by the Insti-
tutional Review Board of the University of Michigan
Medical School. All participants meeting preliminary
qualifications from the telephone screen were sched-
uled for a screening interview and sent a packet that
included the Milcom Health History Questionnaire
and baseline questionnaires which included the
following: general history (to assess demographics);
smoking history; substance intake history; Center
for Epidemiological Studies-Depression (CES-D;
Radloff, 1977); and the Fagerstrom test of nicotine
dependence (FTND; Fagerstrom et al., 1991;
Heatherton et al., 1991; Pomerleau et al., 1994).
At the screening interview, the study was explained
and informed consent obtained. The Milcom was
reviewed to determine medical exclusion, height,
weight and blood pressure were measured, a preg-
nancy test was administered, and a 5 ml blood sample
was withdrawn for baseline cotinine concentrations.
The structured clinical interview for DSM-IV (SCID;
First et al., 1994) was conducted by a trained inter-
viewer to determine history of major depressive disor-
der, mania, hypomania, dysthymia and anorexia
nervosa. Acceptance into the HXþMDD or
HXMDD groups was made on the basis of this inter-
view. To be categorized as HXþMDD, participants
were required to have experienced at least one episode
of MDD with five or more symptoms within the past
10 years. To rule out currently depressed individuals,
they were required not to have had an episode of MDD
or met criteria for dysthymia within the past 6 months.
To qualify as HXMDD, smokers could not have a
history of any depression diagnosis.
The study consisted of two 5-day intervals sepa-
rated by approximately a month and timed to coincide
with the mid- to late-follicular phase (operationally,
between the end of menses and day 11 of the men-
strual cycle)—the time when affective, physiological
and hormonal responses are known to be ‘low’ or neu-
tral (Schechter et al., 1989). During one 5-day interval
the participant smoked ad libitum; during the other 5-
day interval, she abstained from smoking; conditions
were presented in counterbalanced order. CO levels
(CO 10) were measured on all 5 days, and a urine
sample was obtained on day 3 to rule out pregnancy.
On days 4 and 5 of the ad libitum smoking interval, to
maintain a steady state of nicotine during laboratory
testing, the participant was provided with two 15 mg
Nicotrol1 nicotine transdermal patches to be worn
from 1100 h through to the end of the laboratory ses-
sion. On days 3–5 of the abstinence interval, the par-
ticipant also provided a urine sample for testing with a
NicCheckTM test strip for nicotine and its metabolites
for additional verification of abstinence.
For the first 3 days of each interval, the participant
came into the laboratory to receive/drop off her daily
diary questionnaire. This instrument was completed at
bedtime and consisted of a 24-h retrospective assess-
ment of smoking craving and withdrawal symptoma-
tology as specified in DSM-IV (APA, 1994)—
depressed mood, insomnia, irritability, anxiety, diffi-
culty concentrating, restlessness, increased appetite—
measured on a bipolar scale of 5 to þ5 with values
less than zero recoded as zero (Pomerleau et al.,
2001).
On day 4 of each phase, the participant reported for
a laboratory session that began at 1500 h. The partici-
pant was seated in a recliner on one side of the one-
way mirror; an intravenous catheter, attached to infu-
sion-exfusion tubing to allow unobtrusive withdrawal
in an adjacent room, was inserted 60 min prior to
blood sampling to allow time for cortisol levels to sta-
bilize. Samples for cortisol and nicotine/cotinine were
withdrawn at 1600 h; samples for ACTH were with-
drawn four times over a 20 min interval and pooled.
The line was heparinized between draws to prevent
clotting. Samples were collected in standard EDTA
vacutainer tubes which were kept on ice during the
session, centrifuged at 4C, with the plasma stored
at 80C until assayed. Plasma cortisol levels were
measured by RIA, using Diagnostic Product Corpora-
tion’s cortisol CORT-A-COUNT kit. Plasma ACTH
levels were determined using a Nichols Institute Alle-
gro HS-ACTH immunoassay kit. Baseline cotinine
was measured using high performance liquid chroma-
tography (HPLC; Hariharan et al., 1988).
The session lasted approximately 3 h, during which
a modified version the Velten mood induction proce-
dure (VMIP; Velten, 1968) was used as a provocative
assessment of susceptibility to dysphoria. The stan-
dard VMIP induces affect by having participants read
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a series of 50 emotional statements, with encourage-
ment to actualize the feelings suggested by each state-
ment. In the modified version, a pre-recorded tape was
broadcast via speakers placed in the laboratory, con-
sisting of 15 min of neutral statements followed by
15 min of dysphoric-mood statements. The Profile of
Mood States (POMS; McNair et al., 1971) was admi-
nistered once before the neutral statements, once
between the two segments, and once after the depres-
sion statements, with the following instructions:
‘Please read EVERY word carefully. Then fill in
ONE space under the answer which best describes
how you feel RIGHT NOW. Mark the answer which
is closest to how you feel RIGHT NOW using the fol-
lowing numbers . . . .’
Following the session, the participant was given a
1 mg dexamethasone tablet with instructions to take
it at 2300 h—the standard protocol for the dexa-
methasone suppression test (DST; Carroll et al.,
1981). The DST, which involves monitoring the
cortisol response to the administration of a small
amount of the exogenous glucocorticoid, dexametha-
sone, was used to examine systematically the relation-
ship between abstinence-induced dysphoria and
dysregulation of inhibitory feedback mechanism in
the hypothalamic–pituitary–adrenal (HPA) axis.
Depressed individuals are less likely to show the nor-
mal response of cortisol suppression to levels below
1 mg/dl (Baumgartner et al., 1985) and also tend to
show enhanced variability in the range of cortisol
response. ACTH release was also measured in order
to provide additional information about inhibitory
feedback mechanisms.
On day 5 of each phase, the participant reported to
the laboratory at 1500 h and a catheter was inserted as
described above. After 60 min, a single sample for
post-dexamethasone cortisol was withdrawn, and four
samples for ACTH were taken over a 20 min interval
for subsequent pooling.
Data analysis
Baseline differences between diagnostic groups were
compared using independent t-tests and ChiSquare
tests as appropriate. Because of marginally significant
differences in baseline cotinine levels, baseline con-
centrations were covaried in all subsequent analyses.
Tests of withdrawal symptoms over the first 3 days
were conducted using SAS PROC MIXED. Because
preliminary testing revealed no higher-order interac-
tion for any variable, diagnostic group, smoking con-
dition, day and all first-order interactions were
included in the model. Session POMS data were ana-
lysed including diagnostic group, smoking condition,
time (pre- and post-mood induction), and all first-
order interactions, using baseline (pre-neutral state-
ments) as an additional covariate. Cortisol and ACTH
values were log-transformed for the purpose of statis-
tical testing. Because of the potential effect of age on
DST results (Akil et al., 1993), and because of sub-
stantial though nonsignificant group differences in
age, this variable was also included as a covariate.
Because of the possible impact of oral contraceptive
use on cortisol and ACTH levels (Kirshbaum et al.,
1999), two oral contraceptive users matched for group
and contraceptive type (Triphasic) were included in
analyses of these variables; a third oral contraceptive
user, in the HXþMDD group, could not be matched
and was excluded. Data were analysed using SAS
PROC MIXED, with diagnostic group, smoking con-
dition, dexamethasone (pre vs post) and all first-order
interactions included in the model.
RESULTS
Baseline group differences
Baseline characteristics for the two groups are shown
in Table 1. CES-D scores for HXþMDD participants
were higher than for HXMDD. The only other sig-
nificant difference was that cotinine levels were higher
in HXMDD participants.
In the HXþMDD group, four women had had a sin-
gle episode of MDD, seven had had two episodes, and
one had had three. The mean length of time since the
most recent episode was 2.4 2.4 years (range 0–8
years).
Compared with participants who completed the
protocol, the 23 individuals who enrolled but either
did not start or did not complete the protocol were sig-
nificantly older (completers: 31.0 9.5 years; non-
completers: 39.1 12.4 years; t¼2.53, p< 0.05)
and more nicotine dependent as measured by the
Table 1. Participant characteristics (mean SEM or percent; t-test
or ChiSquare)
HXþMDD HXMDD p-value
(n¼ 12) (n¼ 12)
Age (years) 34.0 2.7 28.0 2.5 NS
Race (% white) 83% 83% NS
BMI (kg/m2) 25.2 1.1 27.2 1.6 NS
Smoking rate 17.8 2.3 20.0 1.5 NS
(cigarettes/day)
Cotinine (ng/ml) 186.7 27.2 324.3 61.0 < 0.10
FTND (range 0–10) 4.2 0.5 5.2 0.5 NS
CES-D (range 0–60) 19.7 3.5 6.6 1.8 < 0.05
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FTND (completers: 4.7 1.8; noncompleters:
6.0 2.2; t¼2.26, p< 0.05). They did not differ
significantly with respect to race distribution or
cigarettes/day.
Craving and withdrawal effects over the first
three days
Craving and withdrawal symptomatology over the 3-
day pre-session period are shown in Figure 1. For
craving, a significant main effect emerged for condi-
tion (smoking vs abstinence; F[1,20]¼ 21.94,
p< 0.0001), with a marginal interaction of condition
with diagnostic group (F[1,20]¼ 3.78, p< 0.10), such
that craving during abstinence was most strongly ele-
vated in HXMDD. Significant or marginal main
effects were detected for both diagnostic group and
condition for irritability (diagnostic group: F[1,22]
¼ 6.33, p< 0.05; condition: F[1,20]¼ 14.75, p<
0.01), anxiety (diagnostic group: F[1,22]¼ 3.45,
p< 0.10; condition: F[1,20]¼ 19.38, p< 0.001), diffi-
culty concentrating (diagnostic group: F[1,22]¼ 3.26,
p< 0.10; condition: F[1,20]¼ 10.43, p< 0.01), and
restlessness (diagnostic group: F[1,22]¼ 5.35,
p< 0.05; condition: F[1,20]¼ 19.08, p< 0.001). Sig-
nificant or marginal main effects for diagnostic group
only were detected for depression (F[1,22]¼ 13.76,
p< 0.01) and insomnia (F[1,22]¼ 3.27, p< 0.10).
Significant main effects for condition only were
detected for increased appetite (F[1,20]¼ 14.72,
p< 0.01). Except for a marginal diagnostic group
by day interaction for insomnia (F[2,44]¼ 2.74,
p< 0.10), no interaction effects for withdrawal symp-
toms were observed.
Response to mood induction
Response to mood induction is shown in Figure 2. A
time effect was observed for the POMS elated/
depressed subscale (F[1,22]¼ 42.67, p< 0.0001),
indicating that the mood induction procedure was
successful. Significant differences were also observed
for diagnostic group (F[1,22]¼ 9.05, p< 0.01), with
the HXþMDD group evincing a greater overall level
of depression than the HXMDD group. Regarding
the remaining scales, significant time effects were also
observed for composed/anxious (F[1,22]¼ 4.72, p<
0.05), agreeable/hostile (F[1,22]¼ 15.80, p< 0.001),
onfident/unsure (F[1,22]¼ 9.11, p< 0.01) and
energetic/tired (F[1,22]¼ 18.81, p< 0.001). Signifi-
cant group differences were detected for agreeable/
hostile (F[1,22]¼ 7.28, p< 0.05), with a trend
towards significant differences for energetic/tired
(F[1,22]¼ 2.97, p< 0.10). No significant effects for
smoking condition or for any interaction for elated/
depressed or any other POMS scale were observed.
Cortisol and ACTH
Data for 11 HXMDD and 11 HXþMDD partici-
pants were available for analysis of cortisol; an addi-
tional participant had missing ACTH data, leaving 10
cases in the HXþMDD group available for ACTH
analysis. The results for cortisol and ACTH are
shown in Figure 3. Comparison of pre-session values
showed no significant differences based on either
smoking condition or depression status for either
cortisol or ACTH (expressed as continuous vari-
ables). Comparisons of pre- vs post-dexamethasone
administration showed highly significant post-
dexamethasone suppression of both cortisol
(F[1,20]¼ 370.83, p< 0.0001) and ACTH (F[1,19]
¼ 27.72, p< 0.0001); no participant in either group
exhibited DST nonsuppression during either the
smoking or abstinence condition, using 5 mg/dl as
the cutoff. For ACTH, but not cortisol, a trend towards
significant between-groups differences was detected
(F[1,18]¼ 3.20, p< 0.10), with levels for the
HXþMDD group exceeding those for the HXMDD
MDD group. No significant differences or trends were
detected for either cortisol or ACTH for smoking
condition (ad libitum smoking vs abstinence) or any
interaction.
DISCUSSION
Baseline characteristics for HXþMDD and
HXMDD women smokers were similar in most
respects. The HXþMDD participants exhibited higher
CES-D scores than the HXMDD participants but
this was expected given that they were selected on
the basis of diathesis for depression. Cotinine levels
showed a trend towards being higher in the
HXMDD participants, which was unrelated to the
selection criteria and seems adventitious; differences
in cigarettes/day or degree of dependence were in a
consistent direction but fell short of being a trend.
As expected, significant main effects for condition
(smoking vs abstinence) were detected for craving and
most withdrawal symptoms. More surprisingly,
regardless of smoking condition, we found greater
overall levels of affective smoking-withdrawal symp-
tomatology (irritability, anxiety, difficulty concentrat-
ing, restlessness, depression and insomnia) in history-
positive participants despite their lower baseline
levels of nicotine intake. Withdrawal symptomatology
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Figure 1. Craving and withdrawal symptoms over 3 days (means on a scale of 0–5). Open circles: HXMDD, ad libitum smoking; open
squares: HXMDD, smoking abstinence; filled circles: HXþMDD, ad libitum smoking; filled squares: HXþMDD, smoking abstinence
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has been reliably demonstrated even in minimally
deprived smokers, being lowest immediately after
smoking and rising measurably within half an hour
to an hour (Pomerleau et al., 1983), at which point
dependent smokers typically light up another cigar-
ette. Although no differential effects were observed
based on several days’ abstinence vs ad libitum smok-
ing, our findings suggest that individuals with a dia-
thesis for depression may experience more chronic
distress from withdrawal symptomatology than their
nondepressed counterparts. This circumstance may
contribute to relapse, unsuccessful quitting, or failure
Figure 2. Mood ratings on POMS subscales (means on scales of 0–36) before and after the Velten mood induction procedure (day 4). Open
circles: HXMDD, ad libitum smoking; open squares: HXMDD, smoking abstinence; filled circles: HXþMDD, ad libitum smoking;
filled squares: HXþMDD, smoking abstinence
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even to initiate a quit attempt in smokers with a his-
tory of depression. By contrast, craving did not differ
based on diagnostic group, and indeed, a marginal
interaction of condition with diagnostic group
emerged such that craving during abstinence was most
strongly elevated in nondepressed smokers—prob-
ably reflecting their higher nicotine intake as indicated
by baseline cotinine levels. This disjunction between
craving and affective withdrawal symptoms lends
further support to our contention that these patterns
may represent distinct phenotypes for smoking (e.g.
Pomerleau et al., 2000).
The modified Velten mood induction procedure was
effective in increasing self-reported depressed mood,
as measured by the POMS elated/depressed subscale
in both history positive and history negative partici-
pants, and also increased negative responses on sev-
eral other POMS subscales. A number of overall
group differences were observed, suggesting that the
HXþMDD group may have experienced greater
depression than the HXMDD group. No significant
main effects for smoking condition nor any inter-
action effects emerged, however; little evidence was
found for a differential effect of abstinence on sus-
ceptibility to acute mood induction by history of
depression.
The results for HPA axis hormones are not as
easily characterized. Regarding the effects of smoking
Figure 3. Pre- and post-DST levels of cortisol and ACTH (mean SEM) (days 4 and 5). Shaded bars: pre-dexamethasone condition; dark
bars: post-dexamethasone condition
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abstinence on cortisol, conflicting evidence has been
presented in the literature. In two previous studies
involving the DST in smokers, for example, Hughes
et al. (1988) found a significant increase in baseline
(pre-dexamethasone) cortisol in nondepressed labora-
tory participants after 1–2 days’ abstinence, whereas
Frederick et al. (1998) found a significant decrease
in baseline cortisol in quitting smokers at 2 and 4
weeks. In our study, in which confirmed abstinence
was required and history of depression was included
as a grouping factor, there were no changes in
baseline cortisol or ACTH levels after 4 days’
abstinence. Although our findings cannot be reg-
arded as conclusive in light of discrepancies in the
previously cited studies, they indicate that investiga-
tions using repeated measures over both short- and
long-term abstinence will be needed to resolve the
issue.
All participants in our study evinced cortisol sup-
pression in response to dexamethasone (i.e. none
escaped from suppression) during both smoking and
abstinence conditions (using 5 mg/dl as the cutoff),
and no differences were found in degree of suppres-
sion as a function of either abstinence or history of
depression. An explanation proposed by Hughes
et al. (1988) upon failure to observe elevated cortisol
levels following dexamethasone administration dur-
ing 1–2 days’ smoking abstinence in nondepressed
smokers is that, as with baseline cortisol, a longer per-
iod of abstinence may be needed to elicit HPA dysre-
gulation. No changes were found in degree of
suppression over time over 5 days’ abstinence, how-
ever, and Frederick et al. (1998) found no interaction
for time by percent suppression over 2 and 4 weeks
after quitting, suggesting that time alone may not be
the critical variable.
Another and perhaps more likely possibility is
that a negative bias may have been introduced by
the study design: Not only were persons with current
diagnosis of major depression and/or taking an anti-
depressant excluded, but also participants were told
they would be abstaining only for a time-limited
interval rather than actually quitting smoking. These
methodological considerations, though conserva-
tive, may have limited the ability of the present
design to elicit a degree of depression/dysphoria suf-
ficient to precipitate escape from dexamethasone
suppression. We note, moreover, that only 40%–
50% of patients with current diagnosis of MDD typi-
cally exhibit escape from dexamethasone suppres-
sion when tested (Ribeiro et al., 1993), suggesting
that the DST in its present form may not be sensitive
enough to detect more subtle degrees of HPA dysre-
gulation accompanying moderate depression/dys-
phoria induced by smoking abstinence. Providing
some support for this speculation are our findings
on ACTH, a measure that provides additional infor-
mation about pituitary control mechanisms for corti-
sol release. ACTH levels trended toward overall
elevation in HXþMDD smokers and appear to show
almost no suppression in the abstinence condition in
this group, though the interaction effect failed to
reach significance. It should be noted that interpreta-
tion of our findings is complicated by the fact that
HXþMDD smokers included women with both sin-
gle- and multiple episodes—which contribute varia-
bility in HPA axis response—and with recency
ranging from zero to 8 years. Differences in age
and BMI, though not significant, may also have con-
tributed variability in our results. We conclude that
research in a larger and/or more severely depressed
sample in an inpatient setting, including men as well
as women, and incorporating additional measures of
HPA function and frequent sampling of cortisol and
ACTH over a longer period of time, ought to be con-
ducted before the possibility of exacerbation of HPA
dysregulation during smoking abstinence is dis-
missed. We hope that the present report will stimu-
late further inquiry along these lines.
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